Cargando…
Targeting Semaphorin 3C in Prostate Cancer With Small Molecules
Despite the amenability of early-stage prostate cancer to surgery and radiation therapy, locally advanced and metastatic prostate cancer is clinically problematic. Chemical castration is often used as a first-line therapy for advanced disease, but progression to the castration-resistant prostate can...
Autores principales: | Lee, Chung C W, Munuganti, Ravi Shashi Nayana, Peacock, James W, Dalal, Kush, Jiao, Ivy Z F, Shepherd, Ashley, Liu, Liangliang, Tam, Kevin J, Sedgwick, Colin G, Bhasin, Satyam, Lee, Kevin C K, Gooding, Luke, Vanderkruk, Benjamin, Tombe, Tabitha, Gong, Yifan, Gleave, Martin E, Cherkasov, Artem, Ong, Christopher J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280316/ https://www.ncbi.nlm.nih.gov/pubmed/30534631 http://dx.doi.org/10.1210/js.2018-00170 |
Ejemplares similares
-
Dependency of Tamoxifen Sensitive and Resistant ER(+) Breast Cancer Cells on Semaphorin 3C (SEMA3C) for Growth
por: Bhasin, Satyam, et al.
Publicado: (2023) -
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells
por: Yenki, Parvin, et al.
Publicado: (2023) -
Androgen receptor transcriptionally regulates semaphorin 3C in a GATA2-dependent manner
por: Tam, Kevin J., et al.
Publicado: (2016) -
Semaphorin 3 C drives epithelial-to-mesenchymal transition, invasiveness, and stem-like characteristics in prostate cells
por: Tam, Kevin J., et al.
Publicado: (2017) -
Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers
por: Singh, Kriti, et al.
Publicado: (2018)